MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial

British Journal of Cancer

Volumn 109, Issue 5, 2013, Pages 1243-1251

  Hansen, T F ^a,b   Christensen, R D P ^b   Andersen, R F ^a,b   Sorensen F B ^a,b   Johnsson, A ^c   Jakobsen, A ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

angiogenesis; chemotherapy; colorectal neoplasms; epidermal growth factor like domain 7; microRNA; predictive biomarkers

Indexed keywords

BEVACIZUMAB; CALDESMON; CAPECITABINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR LIKE DOMAIN 7; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; IRINOTECAN; MICRORNA 126; OXALIPLATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE SECTION; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DENMARK; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MICRORNAS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SWEDEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883742865     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.448     Document Type: Article

References (32)

1. Boni V, Zarate R, Villa JC, Bandres E, Gomez MA, Maiello E, Garcia-Foncillas J, Aranda E (2011) Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J 11: 429-436.
2. Campagnolo L, Leahy A, Chitnis S, Koschnick S, Fitch MJ, Fallon JT, Loskutoff D, Taubman MB, Stuhlmann H (2005) EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. Am J Pathol 167: 275-284. (Pubitemid 40884788)
3. Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z (2009) A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 24: 677-685.
4. Chang KH, Mestdagh P, Vandesompele J, Kerin MJ, Miller N (2010) MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 10: 173.
5. Delfortrie S, Pinte S, Mattot V, Samson C, Villain G, Caetano B, Lauridant-Philippin G, Baranzelli MC, Bonneterre J, Trottein F, Faveeuw C, Soncin F (2011) Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation. Cancer Res 71: 7176-7186.
6. Diaz R, Silva J, Garcia JM, Lorenzo Y, Garcia V, Pena C, Rodriguez R, Munoz C, Garcia F, Bonilla F, Dominguez G (2008) Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 47: 794-802.
7. Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
8. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
9. Filipowicz W, Bhattacharyya SN, Sonenberg N (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114.
10. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D (2008) miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15: 272-284.
11. Guo C, Sah JF, Beard L, Willson JKV, Markowitz SD, Guda K (2008) The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signalling and is frequently lost in colon cancers. Genes Chromosomes Cancer 47: 939-946.
12. Hansen TF, Christensen Rd, Andersen RF, Spindler KL, Johnsson A, Jakobsen A (2011) The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: Results from the Nordic ACT trial. Int J Colorectal Dis 27(6): 715-720.
13. Hansen TF, Soerensen FB, Lindebjerg J, Jakobsen A (2012) The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. BMC Cancer 12: 83.
14. Harnprasopwat R, Ha D, Toyoshima T, Lodish H, Tojo A, Kotani A (2010) Alteration of processing induced by a single nucleotide polymorphism in pri-miR-126.Biochem Biophys Res Commun 399: 117-122.
15. Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, Chen CZ, Kuo CJ (2008) Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126.Development 135: 3989-3993.
16. Li JJ, Yang XM, Wang SH, Tang QL (2011) Prognostic role of epidermal growth factor-like domain 7 protein expression in laryngeal squamous cell carcinoma. J Laryngol Otol 125: 1152-1157.
17. Li XM, Wang AM, Zhang J, Yi H (2010) Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med Oncol 28: 1054-1057.
18. Louvet C, De GA, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M (2001) Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 91: 2033-2038. (Pubitemid 32479191)
19. Meister J, Schmidt MH (2010) miR-126 and miR-126: new players in cancer. Sci World J 10: 2090-2100.
20. Nichol D, Stuhlmann H (2012) EGFL7: a unique angiogenic signalling factor in vascular development and disease. Blood 119: 1345-1352.
21. Parker LH, Schmidt M, Jin SW, Gray AM, Beis D, Pham T, Frantz G, Palmieri S, Hillan K, Stainier DY, De Sauvage FJ, Ye W (2004) The endothelial-cell- derived secreted factor Egfl7 regulates vascular tube formation. Nature 428: 754-758. (Pubitemid 38514720)
22. Png KJ, Halberg N, Yoshida M, Tavazoie SF (2011) A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 481: 190-194.
23. Schepeler T, Holm A, Halvey P, Nordentoft I, Lamy P, Riising EM, Christensen LL, Thorsen K, Liebler DC, Helin K, ∅rntoft TF, Andersen CL (2012) Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes. Oncogene 31: 2750-2760.
24. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, Wiuf C, Sorensen FJ, Kruhoffer M, Laurberg S, Kauppinen S, Orntoft TF, Andersen CL (2008) Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 68: 6416-6424.
25. Schmidt M, Paes K, De MA, Smyczek T, Yang S, Gray A, French D, Kasman I, Klumperman J, Rice DS, Ye W (2007) EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development 134: 2913-2923. (Pubitemid 47386904)
26. Sun Y, Bai Y, Zhang F, Wang Y, Guo Y, Guo L (2010) miR-126 inhibits nonsmall cell lung cancer cells proliferation by targeting EGFL7. Biochem Biophys Res Commun 391: 1483-1489.
27. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147-152.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
29. Wagner AD, Arnold D, Grothey AA, Haerting J, Unverzagt S (2009) Antiangiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev 3: CD005392.
30. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, Bassel-Duby R, Olson EN (2008) The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 15: 261-271.
31. Wu F, Yang LY, Li YF, Ou DP, Chen DP, Fan C (2009) Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology 50: 1839-1850.
32. Yang R, Dick M, Marme F, Schneeweiss A, Langheinz A, Hemminki K, Sutter C, Bugert P, Wappenschmidt B, Varon R, Schott S, Weber BH, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, Muller H, Arndt V, Brenner H, Sohn C, Burwinkel B (2011) Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. Breast Cancer Res Treat 127: 549-554.